Moderna
MRNA
$6.38 (11.48%)
1D
1W
3M
1Y
5Y
ALL
Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, and systemic intracellular therapeutics.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Zacks Investment Research • 10 hours ago • MRNA
MRNA Stock Jumps as FDA Briefing Docs Ease Flu Shot Approval Concerns
Zacks Investment Research • 1 day ago • MRNA
Moderna (MRNA) Surges 6.3%: Is This an Indication of Further Gains?
Benzinga • 1 day ago • MRNA
FDA Panel Set To Debate Moderna Flu Shot
Accesswire • 1 day ago • MRNA
Moderna to Host Investor Event - Science Day
Reuters • 1 day ago • MRNA
Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.